Table 3.
Comparative analysis of variables changes between baseline and 72 h after treatment
Patients |
PMX-HP (n = 20) |
Control (n = 20) |
P value | ||
To1 | T722 | To3 | T724 | ||
SOFA score | 11.2 ± 5.8 | 4.7 ± 3.5 | 10.0 ± 4.0 | 8.7 ± 7.3 | 0.047a |
Respiratory SOFA | 2.6 ± 1.0 | 1.9 ± 1.0 | 2.6 ± 1.5 | 1.8 ± 1.0 | 0.799 |
Cardiovascular SOFA | 3.4 ± 1.2 | 0.4 ± 0.9 | 2.3 ± 1.8 | 1.2 ± 1.3 | 0.072 |
Liver SOFA | 0.7 ± 0.9 | 1.1 ± 1.5 | 0.7 ± 1.3 | 1.4 ± 1.3 | 0.683 |
Renal SOFA | 2.6 ± 1.0 | 0.7 ± 1.0 | 2.6 ± 1.5 | 2.8 ± 1.6 | 0.000a |
Coagulation SOFA | 1.6 ± 1.5 | 1.3 ± 1.3 | 1.2 ± 1.2 | 2.8 ± 1.8 | 0.014a |
WBC, 109/L | 87.7 ± 65.0 | 102.5 ± 62.7 | 94.0 ± 49.1 | 115.6 ± 59.0 | 0.552 |
Hb, g/L | 9.6 ± 2.0 | 9.0 ± 0.9 | 10.5 ± 2.2 | 9.7 ± 1.0 | 0.024a |
Inotropic score | 163.7 ± 302.1 | 8.9 ± 19.1 | 90.8 ± 181.7 | 1.4 ± 4.2 | 0.006a |
VDI | 2.4 ± 3.4 | 0.1 ± 0.3 | 1.0 ± 2.0 | 0.0 ± 0.1 | 0.001a |
Immediately after completion of two session of polymyxin B hemoperfusion (PMX-HP);
Seventy-two hours after completion of two session of PMX-HP;
Immediately after surgical control;
Seventy-two hours after conventional standard therapy according to survival sepsis campaign.
P < 0.05, compared with variables between just before initiating treatment and 72 h after initiating the treatment in PMX-HP group and control group. SOFA: Sequential organ failure assessment; WBC: White blood cell; Hb: Hemoglobin; VDI: Vasopressor dependency index; PMX-HP: Polymyxin B hemoperfusion.